
## Leandro Blas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1141036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 431.e9-431.e13.	1.6	19
2	Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review. Current Urology Reports, 2021, 22, 25.	2.2	9
3	Value of prostate-specific antigen density in negative or equivocal lesions on multiparametric magnetic resonance imaging. Turkish Journal of Urology, 2020, 46, 367-372.	1.3	8
4	Impact of nerve sparing in robotâ€assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence. International Journal of Urology, 2022, 29, 824-829.	1.0	7
5	Longâ€ŧerm outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80Âyears old. Cancer Science, 2021, 112, 3074-3082.	3.9	6
6	Validation of models predicting lymph node involvement probability in patients with prostate cancer. International Journal of Urology, 2022, 29, 428-434.	1.0	6
7	Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy. Cancers, 2022, 14, 2696.	3.7	6
8	Predictive factors of survival outcomes in firstâ€line therapy for metastatic castrationâ€resistant prostate cancer. International Journal of Urology, 2022, 29, 26-32.	1.0	5
9	Urinary manifestations in Isaacs's syndrome. Our experience in 8 cases. Neurourology and Urodynamics, 2018, 37, 496-500.	1.5	4
10	Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. Prostate International, 2022, 10, 7-13.	2.3	4
11	Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer. Anticancer Research, 2021, 41, 3885-3889.	1.1	3
12	Kidney failure, status passage, and the transitional nature of living with the disease: A qualitative study in Argentina. Health (United Kingdom), 2021, , 136345932110468.	1.5	3
13	Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. Prostate International, 2021, 10, 50-55.	2.3	3
14	How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina. Social Science and Medicine, 2022, 293, 114666.	3.8	3
15	The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 733.e17-733.e24.	1.6	2
16	Water knot: Case report of a rare complication during a urodynamic test. Journal of Clinical Urology, 2021, 14, 503-504.	0.1	1
17	Renal tumor growth rate in patients with previously normal CT scan: Analysis of the initial stage of growth. Turkish Journal of Urology, 2021, 47, 9-13.	1.3	1
18	Unrecognized Pitfall When Doing Nerve-Sparing Surgery in Radical Prostatectomy. Annals of Surgical Oncology, 2021, 28, 4775-4776.	1.5	1

Leandro Blas

#	Article	IF	CITATIONS
19	Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. JMA Journal, 2022, 5, 83-90.	0.8	1
20	Aggressive primary renal synovial sarcoma in a young male: Case report and literature review. Journal of Clinical Urology, 2020, , 205141582092629.	0.1	0
21	Initial experience in the treatment of Peyronie's disease using testicular vaginal tunica graft. Journal of Clinical Urology, 0, , 205141582110166.	0.1	Ο
22	Seminal vesicle leiomyosarcoma: Case report and literature review. Urologia, 2021, , 039156032110284.	0.7	0
23	Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer. Anticancer Research, 2021, 41, 5593-5598.	1.1	0